Colorectal Cancer Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Chemotherapy, Immunotherapy), By Country (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022

Table of Contents

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Information or Data Analysis
1.2.1 Market formulation & validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
3.1 Disease Primer
3.1.1 Stages:
3.1.2 Symptoms
3.1.3 Risk Factors
3.2 Epidemiology by Indications
3.3 Current Prevalence for Seven Major Markets (U.S., Japan, EU5)
3.4 Current Incidence of Seven Major Markets (U.S., Japan, EU5)
3.5 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
Chapter 4 Global Colorectal Cancer Drugs Market Overview
4.1 Introduction and Market Overview
4.1.1 Segmentation, by Drug Class
4.1.1.1 Chemotherapy
4.1.1.1.1 Antimetabolites
4.1.1.1.2 Alkylating agents
4.1.1.2 Immunotherapy
4.1.1.2.1 Biologic Response Modifiers
4.1.1.2.2 Colony-Stimulating Factors
4.1.1.2.3 Tumor Vaccines
4.1.1.2.4 Monoclonal Antibodies
4.1.2 Segmentation, by Region
4.1.2.1 U.S.
4.1.2.2 U.K.
4.1.2.3 Germany
4.1.2.4 Spain
4.1.2.5 Italy
4.1.2.6 France
4.1.2.7 Japan
4.1.3 Market size and forecast
4.1.4 Sales performance
4.1.5 Market share distribution
4.1.6 Market dynamics among leading brands
4.2 Patent Expiry Schedule
4.3 Drivers and Challenges
4.4 M&A, Deal Landscape (YTD 2013-2018)
4.5 Pricing and Reimbursement
4.6 Emerging Markets
4.6.1 India
4.6.2 China
4.6.3 South Korea
4.7 SWOT Analysis
第五章结直肠癌药物市场:管道Intelligence
5.1 Pipeline Landscape
5.1.1 Drugs in development
5.1.2 Key R&D trends
5.1.2.1 Molecular targeted therapy
5.1.2.2 Immunotherapy
5.1.2.3 Biosimilars
5.2 Promising Drugs
5.2.1 Late-stage pipeline
5.2.2 Profile of disruptive drugs
5.2.2.1 Tecentriq
5.2.2.2 Binimetinib+Encorafenib+Cetuximab
5.2.2.3 MK-3475-177
5.2.2.4 Napabucasin
Chapter 6 Company Profiles
6.1 Amgen
6.1.1 Company overview
6.1.2 Current product portfolio
6.1.3 Product forecast sales up to 2022
6.1.4 Company - Key news flow
6.1.5 Pipeline view
6.1.6 Pipeline forecast
6.1.7 Catalysts and event calendar
6.1.8 SWOT analysis
6.2 Bayer
6.2.1 Company overview
6.2.2 Current product portfolio
6.2.3 Product forecast sales up to 2022
6.2.4 Company - Key news flow
6.2.5 Pipeline view
6.2.6 Pipeline forecast
6.2.7 Catalysts and event calendar
6.2.8 SWOT analysis
6.3 Bristol-Myers Squibb
6.3.1公司概述
6.3.2 Current product portfolio
6.3.3 Product forecast sales up to 2022
6.3.4 Company - Key news flow
6.3.5 Pipeline view
6.3.6 Pipeline forecast
6.3.7 Catalysts and event calendar
6.3.8 SWOT analysis
6.4 Eli Lilly
6.4.1 Company overview
6.4.2 Current product portfolio
6.4.3 Product forecast sales up to 2022
6.4.4 Company - Key news flow
6.4.5 Catalysts and event calendar
6.4.6 SWOT analysis
6.5 Merck
6.5.1 Company overview
6.5.2 Current product portfolio
6.5.3 Product forecast sales up to 2022
6.5.4 Company - Key news flow
6.5.5 Pipeline view
6.5.6 Pipeline forecast
6.5.7 Catalysts and event calendar
6.5.8 SWOT analysis
6.6 Roche
6.6.1 Company overview
6.6.2 Current product portfolio
6.6.3 Product forecast sales up to 2022
6.6.4 Company - Key news flow
6.6.5 Pipeline view
6.6.6 Pipeline forecast
6.6.7 Catalysts and event calendar
6.6.8 SWOT analysis
6.7 Sanofi
6.7.1 Company overview
6.7.2 Current product portfolio
6.7.3 Product forecast sales up to 2022
6.7.4 Company - Key news flow
6.7.5 SWOT analysis
Chapter 7 Market Outlook
7.1 What the Future Holds
7.2 Winners and Losers
7.3 Emerging Companies
7.4 The Road Ahead

List of Tables

TABLE 1 Current Colorectal Cancer Prevalence Across Seven Major Markets - 2016
TABLE 2 Current Colorectal Cancer Incidence Across Seven Major Markets - 2016
TABLE 3 Forecast Colorectal Cancer Prevalence across Seven Major Markets, 2016 - 2022
TABLE 4 Forecast Colorectal Cancer Incidence across Seven Major Markets, 2016 - 2022
TABLE 5 Colorectal Cancer Drugs Market Size and Forecast (in $million)
TABLE 6 Geographic Sales Performance by Seven Major Markets (in $million)
TABLE 7 Colorectal Cancer Drugs Market by Drug Class (in $million)
TABLE 8 Forecast Sales of Leading Brands (in $million)
TABLE 9 Global Colorectal Cancer Drugs Pipeline Forecast
TABLE 10 Global Colorectal Cancer Drugs Pipeline Sales Forecast (in $million)
表11结直肠癌药物销售预测Company (in $million)
TABLE 12 Colorectal Cancer Drugs Market Share by Company (in $million)
TABLE 13 Colorectal Cancer Drugs Market: Patent Expiry Schedule
TABLE 14 Colorectal Cancer Deal Landscape YTD (2013 - 2018)
TABLE 15 Colorectal Cancer Drugs in Development
TABLE 16 Late-Stage Colorectal Cancer Pipeline
TABLE 17 Profile of Disruptive Drug: Tecentriq
TABLE 18 Profile of Disruptive Drug: Binimetinib+Encorafenib+Cetuximab
TABLE 19 Profile of Disruptive Drug: MK-3475-177
TABLE 20 Profile of Disruptive Drug: Napabucasin
TABLE 21 Product Portfolio: Vectibix
TABLE 22 Product Portfolio: Mvasi
TABLE 23 Vectibix Sales Forecast Through 2022
TABLE 24 Mvasi Sales Forecast Through 2022
TABLE 25 Amgen Pipeline View
TABLE 26 Amgen Catalysts and Event Calendar
TABLE 27 Product Portfolio: Stivarga
TABLE 28 Stivarga Sales Forecast Through 2022
TABLE 29 Bayer Pipeline View
TABLE 30 Bayer Catalysts and Event Calendar
TABLE 31 Product Portfolio: Opdivo
TABLE 32 Opdivo Sales Forecast Through 2022
TABLE 33 Bristol Myers Squibb Pipeline View
TABLE 34 Bristol Myers Squibb Catalysts and Event Calendar
TABLE 35 Product Portfolio: Cyramza
TABLE 36 Product Portfolio: Erbitux
TABLE 37 Cyramza Sales Forecast Through 2022
TABLE 38 Erbitux Sales Forecast Through 2022
TABLE 39 Eli Lilly Catalysts and Event Calendar
TABLE 40 Product Portfolio: Keytruda
TABLE 41 Keytruda Sales Forecast Through 2022
TABLE 42 Merck Pipeline View
TABLE 43 Merck Catalysts and Event Calendar
TABLE 44 Product Portfolio: Avastin
TABLE 45 Product Portfolio: Xeloda
TABLE 46 Avastin Sales Forecast Through 2022
TABLE 47 Xeloda Sales Forecast Through 2022
TABLE 48 Roche Pipeline View
TABLE 49 Roche Catalysts and Event Calendar
TABLE 50 Product Portfolio: Zaltrap
TABLE 51 Product Portfolio: Eloxatin
TABLE 52 Zaltrap Sales Forecast Through 2022
TABLE 53 Eloxatin Sales Forecast Through 2022

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Stages of colorectal cancer
FIG. 8 Current prevalence across seven major markets - 2016
FIG. 9 Current incidence across seven major markets - 2016
FIG. 10 Geographic sales performance by seven major markets in 2016
FIG. 11 Colorectal cancer drugs market by drug class
FIG. 12 Colorectal cancer drugs market share by company 2016 - 2022
FIG. 13 Market trends & outlook
FIG. 14 Market driver relevance analysis (Current & future impact)
FIG. 15 Market restraint relevance analysis (Current & future impact)
FIG. 16 SWOT analysis (Colorectal cancer drugs market)
FIG. 17 SWOT analysis (Amgen)
FIG. 18 SWOT analysis (Bayer)
FIG. 19 SWOT analysis (Bristol Myers Squibb)
FIG. 20 SWOT analysis (Eli Lilly)
FIG. 21 SWOT analysis (Merck)
FIG. 22 SWOT analysis (Roche)
FIG. 23 SWOT analysis (Sanofi)